AstraZeneca_NNP Annual_JJ Report_NNP and_CC 126_CD Form_NN 20-F_JJ Information_NN 2005_CD NOTES_NNS TO_TO THE_DT FINANCIAL_NNP STATEMENTS_NNS CONTINUED_VBD 25_CD COMMITMENTS_NNS AND_CC CONTINGENT_JJ LIABILITIES_NNS CONTINUED_VBD General_NNP With_IN respect_NN to_TO each_DT of_IN the_DT legal_JJ proceedings_NNS described_VBN above_IN ,_, other_JJ than_IN those_DT which_WDT have_VBP been_VBN disposed_VBN of_IN ,_, we_PRP are_VBP unable_JJ to_TO make_VB estimates_NNS of_IN the_DT loss_NN or_CC range_NN of_IN losses_NNS at_IN this_DT stage_NN ,_, other_JJ than_IN where_WRB noted_VBN in_IN the_DT case_NN of_IN the_DT European_JJ Commission_NNP fine_NN ._.
We_PRP also_RB do_VBP not_RB believe_VB that_IN disclosure_NN of_IN the_DT amount_NN sought_VBN by_IN plaintiffs_NNS ,_, if_IN that_DT is_VBZ known_VBN ,_, would_MD be_VB meaningful_JJ with_IN respect_NN to_TO those_DT legal_JJ proceedings_NNS ._.
This_DT is_VBZ due_JJ to_TO a_DT number_NN of_IN factors_NNS including_VBG :_: the_DT stage_NN of_IN the_DT proceedings_NNS in_IN many_JJ cases_NNS trial_NN dates_NNS have_VBP not_RB been_VBN set_VBN and_CC overall_JJ length_NN and_CC extent_NN of_IN legal_JJ discovery_NN :_: the_DT entitlement_NN of_IN the_DT parties_NNS to_TO an_DT action_NN to_TO appeal_VB a_DT decision_NN :_: clarity_NN as_IN to_TO theories_NNS of_IN liability_NN :_: damages_NNS and_CC governing_VBG law_NN :_: uncertainties_NNS in_IN timing_NN of_IN litigation_NN :_: and_CC the_DT possible_JJ need_NN for_IN further_JJ legal_JJ proceedings_NNS to_TO establish_VB the_DT appropriate_JJ amount_NN of_IN damages_NNS ,_, if_IN any_DT ._.
However_RB ,_, although_IN there_EX can_MD be_VB no_DT assurance_NN regarding_VBG the_DT outcome_NN of_IN any_DT of_IN the_DT legal_JJ proceedings_NNS or_CC investigations_NNS referred_VBD to_TO in_IN this_DT Note_NN 25_CD to_TO the_DT Financial_NNP Statements_NNP ,_, we_PRP do_VBP not_RB expect_VB them_PRP to_TO have_VB a_DT materially_RB adverse_JJ effect_NN on_IN our_PRP$ financial_JJ position_NN or_CC profitability_NN ._.
Taxation_NNP Where_WRB tax_NN exposures_NNS can_MD be_VB quantified_VBN ,_, a_DT provision_NN is_VBZ made_VBN based_VBN on_IN best_JJS estimates_NNS and_CC managements_NNS judgement_NN ._.
Details_NNS of_IN the_DT movements_NNS in_IN relation_NN to_TO material_JJ tax_NN exposures_NNS are_VBP discussed_VBN below_IN ._.
AstraZeneca_NNP had_VBD made_VBN certain_JJ double_JJ taxation_NN relief_NN claims_NNS in_IN accordance_NN with_IN its_PRP$ understanding_NN of_IN existing_VBG law_NN ._.
Management_NNP estimated_VBD that_IN the_DT tax_NN exposure_NN as_IN at_IN 31_CD December_NNP 2004_CD in_IN respect_NN of_IN the_DT issue_NN was_VBD $_$ 197m_CD and_CC the_DT potential_NN for_IN additional_JJ losses_NNS above_IN and_CC beyond_IN the_DT amount_NN provided_VBD was_VBD up_RB to_TO $_$ 130m_CD ,_, although_IN considered_VBN that_IN these_DT additional_JJ losses_NNS were_VBD unlikely_JJ to_TO arise_VB ._.
It_PRP was_VBD also_RB reported_VBN as_IN at_IN 31_CD December_NNP 2004_CD that_WDT AstraZeneca_NNP expected_VBD a_DT definitive_JJ ruling_NN on_IN the_DT matter_NN within_IN the_DT next_JJ 12_CD months_NNS ._.
During_IN the_DT course_NN of_IN 2005_CD ,_, the_DT relevant_JJ law_NN on_IN the_DT availability_NN of_IN credit_NN for_IN foreign_JJ taxes_NNS was_VBD clarified_VBN ,_, confirming_VBG that_IN tax_NN credits_NNS were_VBD to_TO be_VB allowed_VBN in_IN accordance_NN with_IN the_DT original_JJ claims_NNS made_VBN by_IN AstraZeneca_NNP and_CC with_IN retrospective_JJ effect_NN ._.
The_DT Company_NN has_VBZ consequently_RB released_VBN this_DT provision_NN of_IN $_$ 197m_CD to_TO the_DT income_NN statement_NN ._.
AstraZeneca_NNP faces_VBZ a_DT number_NN of_IN transfer_NN pricing_NN audits_NN in_IN jurisdictions_NNS around_IN the_DT world_NN ._.
The_DT issues_NNS under_IN audit_NN are_VBP often_RB complex_JJ and_CC can_MD require_VB many_JJ years_NNS to_TO resolve_VB ._.
Accruals_NNS for_IN tax_NN contingencies_NNS require_VBP management_NN to_TO make_VB estimates_NNS and_CC judgements_NNS with_IN respect_NN to_TO the_DT ultimate_JJ outcome_NN of_IN a_DT tax_NN audit_NN ,_, and_CC actual_JJ results_NNS could_MD vary_VB from_IN these_DT estimates_NNS ._.
The_DT total_JJ accrual_NN included_VBD in_IN the_DT Financial_NNP Statements_NNP to_TO cover_VB the_DT worldwide_JJ exposure_NN to_TO transfer_VB pricing_NN audits_NN is_VBZ $_$ 543m_CD ,_, an_DT increase_NN of_IN $_$ 143m_CD due_JJ to_TO a_DT number_NN of_IN new_JJ audits_NN and_CC revisions_NNS of_IN estimates_NNS relating_VBG to_TO existing_VBG audits_NN ._.
For_IN certain_JJ of_IN the_DT audits_NN ,_, AstraZeneca_NNP estimates_VBZ the_DT potential_NN for_IN additional_JJ losses_NNS above_IN and_CC beyond_IN the_DT amount_NN provided_VBN to_TO be_VB up_RB to_TO $_$ 190m_CD :_: however_RB ,_, management_NN believes_VBZ that_IN it_PRP is_VBZ unlikely_JJ that_IN these_DT additional_JJ losses_NNS will_MD arise_VB ._.
Of_IN the_DT remaining_VBG tax_NN exposures_NNS ,_, the_DT Company_NN does_VBZ not_RB expect_VB material_NN additional_JJ losses_NNS ._.
It_PRP is_VBZ not_RB possible_JJ to_TO estimate_VB the_DT timing_NN of_IN tax_NN cash_NN flows_VBZ in_IN relation_NN to_TO each_DT outcome_NN ._.
Included_VBN in_IN the_DT provision_NN is_VBZ an_DT amount_NN of_IN interest_NN of_IN $_$ 174m_CD ._.
Interest_NN is_VBZ accrued_VBN as_IN a_DT tax_NN expense_NN ._.
26_CD LEASES_NNP Total_NNP rentals_NNS under_IN operating_VBG leases_NNS charged_VBN to_TO the_DT income_NN statement_NN were_VBD as_IN follows_VBZ :_: 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD 155_CD 127_CD 94_CD The_DT future_NN minimum_NN lease_NN payments_NNS under_IN operating_VBG leases_NNS that_WDT have_VBP initial_JJ or_CC remaining_VBG terms_NNS in_IN excess_NN of_IN one_CD year_NN at_IN 31_CD December_NNP 2005_CD were_VBD as_IN follows_VBZ :_: Operating_VBG leases_NNS 2005 2004 2003_CD $_$ m_CD $_$ m_CD $_$ m_CD Obligations_NNS under_IN leases_NNS comprise_VBP Rentals_NNS due_JJ within_IN one_CD year_NN 83 112 112_CD Rentals_NNS due_JJ after_IN more_JJR than_IN one_CD year_NN :_: After_IN five_CD years_NNS 90_CD 69_CD 80_CD From_IN four_CD to_TO five_CD years_NNS 18_CD 28_CD 25_CD From_IN three_CD to_TO four_CD years_NNS 26_CD 35_CD 28_CD From_IN two_CD to_TO three_CD years_NNS 41_CD 45_CD 40_CD From_IN one_CD to_TO two_CD years_NNS 52_CD 63 56 227 240_CD 229 310 352 341_CD
